Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Patients taking the immunotherapy drug Keytruda (pembrolizumab) may now have the option to take it as a quick shot instead of ...

The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is ...

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched this week, to help soften the blow when the original loses patent protection later this decade.

The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance.  Here are five things to know: ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 ...

The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

If you have been watching Merck (MRK) lately, the recent FDA approval for Keytruda QLEX has probably caught your eye. This ...

Because both Opdivo and Keytruda are approved to treat certain types of cancer, you may be able to switch from one drug to the other. Depending on the cancer being treated, there may be specific ...